Last updated: 15 June 2019 at 2:05am EST

Venture Partners Qualified ... Net Worth




The estimated Net Worth of Venture Partners Qualified ... is at least $10.1 Million dollars as of 20 February 2014. Venture Qualified owns over 150,000 units of Concert Pharmaceuticals Inc stock worth over $10,118,660 and over the last 11 years Venture sold CNCE stock worth over $0.

Venture Qualified CNCE stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Concert Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Venture bought 150,000 units of CNCE stock worth $2,100,000 on 20 February 2014.

The largest trade Venture's ever made was buying 150,000 units of Concert Pharmaceuticals Inc stock on 20 February 2014 worth over $2,100,000. On average, Venture trades about 150,000 units every 0 days since 2014. As of 20 February 2014 Venture still owns at least 1,208,920 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Venture Qualified stock trades at the bottom of the page.



Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V..., and Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.



What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.



What does Concert Pharmaceuticals Inc's logo look like?

Concert Pharmaceuticals Inc logo

Complete history of Venture Qualified stock trades at Concert Pharmaceuticals Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
20 Feb 2014 Venture Partners Qualified ...
Buy 150,000 $14.00 $2,100,000
20 Feb 2014
1,208,920


Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: